Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Cost-effectiveness of antiretroviral therapy for prevention.

Kahn JG, Marseille EA, Bennett R, Williams BG, Granich R.

Curr HIV Res. 2011 Sep;9(6):405-15. Review.

2.

Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050.

Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, Sabin ML, Makhlouf-Obermeyer C, De Filippo Mack C, Williams P, Jones L, Smyth C, Kutch KA, Ying-Ru L, Vitoria M, Souteyrand Y, Crowley S, Korenromp EL, Williams BG.

PLoS One. 2012;7(2):e30216. doi: 10.1371/journal.pone.0030216. Epub 2012 Feb 13.

3.

The economics of effective AIDS treatment in Thailand.

Over M, Revenga A, Masaki E, Peerapatanapokin W, Gold J, Tangcharoensathien V, Thanprasertsuk S.

AIDS. 2007 Jul;21 Suppl 4:S105-16.

PMID:
17620745
4.

How HIV treatment advances affect the cost-effectiveness of prevention.

Pinkerton SD, Holtgrave DR.

Med Decis Making. 2000 Jan-Mar;20(1):89-94.

PMID:
10638541
5.

Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.

Pinkerton SD, Holtgrave DR, Pinkerton HJ.

Arch Intern Med. 1997 Sep 22;157(17):1972-80.

PMID:
9308509
6.

Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia.

Marseille E, Giganti MJ, Mwango A, Chisembele-Taylor A, Mulenga L, Over M, Kahn JG, Stringer JS.

PLoS One. 2012;7(12):e51993. doi: 10.1371/journal.pone.0051993. Epub 2012 Dec 20.

7.

Male circumcision at different ages in Rwanda: a cost-effectiveness study.

Binagwaho A, Pegurri E, Muita J, Bertozzi S.

PLoS Med. 2010 Jan 19;7(1):e1000211. doi: 10.1371/journal.pmed.1000211.

8.

The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.

Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB.

AIDS. 2013 Jan 28;27(3):447-58. doi: 10.1097/QAD.0b013e32835ca2dd.

PMID:
23296196
9.

HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions.

Meyer-Rath G, Over M.

PLoS Med. 2012;9(7):e1001247. doi: 10.1371/journal.pmed.1001247. Epub 2012 Jul 10.

10.

The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review.

Mdege ND, Chindove S, Ali S.

Health Policy Plan. 2013 May;28(3):223-36. doi: 10.1093/heapol/czs058. Epub 2012 Jun 26. Review.

11.

Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.

Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, Sanders R, Scotton CR, Soorapanth S, Boily MC, Garnett GP, McElroy PD.

AIDS. 2008 Sep 12;22(14):1829-39. doi: 10.1097/QAD.0b013e32830e00f5.

PMID:
18753932
12.

Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.

Simpson KN, Baran RW, Kirbach SE, Dietz B.

Value Health. 2011 Dec;14(8):1048-54. doi: 10.1016/j.jval.2011.06.011. Epub 2011 Nov 6.

13.

Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence.

Creese A, Floyd K, Alban A, Guinness L.

Lancet. 2002 May 11;359(9318):1635-43. Review. Erratum in: Lancet 2002 Sep 14;360(9336):880.

PMID:
12020523
15.

The epidemiological impact and cost-effectiveness of HIV testing, antiretroviral treatment and harm reduction programs.

Li J, Gilmour S, Zhang H, Koyanagi A, Shibuya K.

AIDS. 2012 Oct 23;26(16):2069-78. doi: 10.1097/QAD.0b013e3283574e54.

PMID:
22781221
16.

HIV treatment as prevention: issues in economic evaluation.

Bärnighausen T, Salomon JA, Sangrujee N.

PLoS Med. 2012;9(7):e1001263. doi: 10.1371/journal.pmed.1001263. Epub 2012 Jul 10. Review.

17.

Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.

Sendi P, Günthard HF, Simcock M, Ledergerber B, Schüpbach J, Battegay M; Swiss HIV Cohort Study.

PLoS One. 2007 Jan 24;2(1):e173.

18.

Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options.

Over M, Marseille E, Sudhakar K, Gold J, Gupta I, Indrayan A, Hira S, Nagelkerke N, Rao AS, Heywood P.

Sex Transm Dis. 2006 Oct;33(10 Suppl):S145-52.

PMID:
17003679
19.
20.

Economics of antiretroviral treatment vs. circumcision for HIV prevention.

Bärnighausen T, Bloom DE, Humair S.

Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21271-6. doi: 10.1073/pnas.1209017110. Epub 2012 Dec 6.

Items per page

Supplemental Content

Write to the Help Desk